CCM
ABBV icon

Compass Capital Management’s AbbVie ABBV Stock Holding History

Compass Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+800
New +$172K 0.01% 91
2025
Q4 		– Sell
-1,083
Closed -$251K – 84
2025
Q3 		$251K Buy
+1,083
New +$221K 0.01% 78

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Compass Capital Management's ABBV Position: Q2 2026 in Review

Compass Capital Management opened a new position in AbbVie (ABBV) in Q2 2026: 800 shares worth $201K. The stake represents 0.01% of the portfolio and ranks #91 among its holdings. This is a return to the name: Compass Capital Management previously reported a position in ABBV as recently as Q3 2025.

Compass Capital Management first reported a position in ABBV in Q3 2025 and has held it in 2 quarters since. The position peaked at $251K in Q3 2025. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Compass Capital Management held 800 shares of AbbVie worth $201K as of Q2 2026.
  • AbbVie was a new Compass Capital Management position in Q2 2026.
  • AbbVie made up 0.01% of Compass Capital Management's portfolio in Q2 2026, its #91 holding.
  • Compass Capital Management first reported a position in AbbVie in Q3 2025 and has held it in 2 quarters since.
  • Compass Capital Management's AbbVie position peaked at $251K in Q3 2025.
  • 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Compass Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.